{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-236468","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.928928+00:00","generated_at":"2026-05-30T16:02:02.531231+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Perspective Therapeutics reports Phase 1/2a data for [212Pb]VMT01; no dose-limiting toxicities observed","bullets":["No dose-limiting toxicities; TEAEs mostly Grades 1–2; no renal toxicities reported despite high renal dosimetry.","At 3.0 mCi dose: 1 RECIST objective response, 2 patients with stable disease at 9 and 11 months.","At 5.0 mCi dose: patients progressed after first or second cycle; findings consistent with preclinical immunostimulatory effect at lower doses.","SMC recommends testing 1.5 mCi dose as monotherapy and in combination with nivolumab; combination cohort now enrolling.","Median 5 prior lines of therapy; FDA Fast Track Designation; plan to update on VMT-α-NET study by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-236468","json":"https://secwatch.observer/filing/0001193125-24-236468.json","markdown":"https://secwatch.observer/filing/0001193125-24-236468.md","text":"https://secwatch.observer/filing/0001193125-24-236468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312524236468/0001193125-24-236468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312524236468/d871448d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:02:02.531231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}